you, Thank Raul.
our the first continued take quarter in our of launch REZ minutes record like discuss REZLIDHIA few progress TAVALISSE, the during I'd growth of with another a Now to -- and half to XXXX. with
adult or approved to thrombocytopenia a chronic FDA indication patients our is CITP, immune insufficient TAVALISSE, see you'll X, for previous with had response an who've for which treatment. Slide On
over achieved quarterly in we X, Slide with XXXX. QX representing to in shipping I'm new another all-time that QX, TAVALISSE clinics high patients growth X,XXX bottles pleased Moving to XX% of
the shipped a quarter in number record since three achieved to patients consecutive highs now launch. clinics have for and bottles of We
we of of achieved new to more increase. representing demand continue $XX.X our year-over-year $X.X than XX% for the million, consistent flow year, quarter QX, net same a grow starting last sales And through We patients million TAVALISSE.
grown how our during the with the carrying year. we first second the pleased to are momentum TAVALISSE half We and half business of this into have look of forward XXXX,
to appropriate growth patients targeted identify entire on for REZLIDHIA. levels who grow TAVALISSE record clinicians to we beyond and we grateful in patient from We TAVALISSE ITP, continuing will starts can launch new continue I'm saw to XXXX. the focus to benefit while team our our the with
chronic in an moving to X, on provide Slide our to update progress the lines have opportunity with wanted earlier of I to we Moving ITP review TAVALISSE in and therapy.
ITP of First are with more XX,XXX are on half and that treated. than patients left, actively than estimate them there the more we recall
are While as steroids steroids line. most are those after therapy, more line XX,XXX first is of the the eligible than and who to second patients of treated on patients third quarters their three patients be in there or still are
second the On XXXX. of has you patients portion the TAVALISSE right, third see and grown since will how line on new
hub of our through been second new that third patients XX% the For we three than or consecutive TAVALISSE quarters, have line. either more capture
are see quarters. earlier past pleased of this We consistency in over on patients very the three TAVALISSE to usage
with more expect to grow due to bottles course persistency earlier As from should continue see the we to treated their patients. refill being TAVALISSE in our are patients those improved we of treatment,
more when is TAVALISSE, reason efficacy that benefits patients the to And to earlier patients after impressed home. the is continuum use message durable increases live who predictable they We'll and These been On results. meaningful TAVALISSE they in are can ITP better have messages promote counts how to hitting day. platelet we on meaningful they X, each the treatment time. chronic our do are count the clinically Clinicians are with over business successful earlier getting and TAVALISSE, the their our Slide durable TAVALISSE of we steroids in platelet using the earlier our that and grow. believe resonating continuing of in increases continue is use
chronic impact patients treatment in the We a of our TAVALISSE's globe to to partners. expansion the Kissei XX, commercial footprint partner the remain Slide in Japan. TAVALISSE with of On ITP that of around launch through our CITP committed the for reminder April, announced continuing
of launching in REZLIDHIA the myeloid our to susceptible with few adult approved for with leukemia first for a patients acute mutation slide the test. Moving FDA-approved as by relapsed to progress I'll you'll slide half is XXXX. XX, XX FDA refractory or minutes take our IDHX which see an REZLIDHIA, indication On continued detected discuss
need and As of acceptable longer Slide and to and or AML, balance provide XX, on particular, introduction response an relapsed that efficacy there unmet be an durations continues an needed. treatments refractory efficacious agents in of targeted in are toxicity for
believe those exactly We addresses that continue strongly needs. REZLIDHIA to
REZLIDHIA. eligible years. whether that more estimates Slide XX,XXX Cancer those within or for patient and with or Moving Society our view patients intensive The treated X our XX, American XXXX, the to of are relapse be with not, research in diagnosed that are patients treatment than therapy of will most refractory patients, showed and currently population to AML
having in with believe mutant of refractory patients the mutation, X% relapsed the lives setting have to to around IDHX opportunity X,XXX each we IDHX Specifically a new near-term X% year. the or patients we of impact
grew quarter at $X.X shipped sales were bottles demand XXX $X.X those directly Slide We XX refractory bringing with sales shows AML in the mutant to our our second representing XX% total product our to million. clinics, relapsed net now total of continued quarter, a XXX X,XXX in early launch patients. IDHX of QX. million REZLIDHIA over bottles of second those REZLIDHIA sold patients progress or and and growth to launch-to-date
remain through growing teams to activities. continue field our awareness and We on focused of other REZLIDHIA
Moving in to scientific and progress we both XX, awareness Slide solid through growing that made publications. on QX activities promotional
Rigel ASCO at go left, meeting durable on launched there. we fingertips. opportunity the our expectations and have and for a annual our had at campaign patient we websites and possible visitors first information presence officially REZLIDHIA.com June. early TAVALISSE a your the that, transform strong First we REZLIDHIA, promote wealth our the both HCP to REZLIDHIA with both It updated resources was major conference remission and is their and to To of campaign have along with in
the slide, QX. scientific progress this the have front on significant On see side right the made you we in will of
in article the data". positioning HMA was mutant of in REZLIDHIA [ph] In olutasidenib discussing IDHX First "recommend in author's review May, Blood the there conclusion, olutasidenib AML in landscape. the Venetoclax failures an given published the available excellent treatment the Advances plus
this reported during also they and Hybrid relevant poster represent at data of AML. patients prognosis previously results. is population and Congress advance patient referring who That Frankfort authors Venetoclax. was our mutant in therapeutic with molecularly of durable treated very refractory The Association the or June. the XXXX a consistent population poor held this Hematology that previously meaningful in were induce were treatment quarter European with that observed presented very olutasidenib with to relapsed IDPX the remissions defined clinically The activity focuses conclusions clinically were on this The wrote
was have since affairs as data and medical the promising They several leukemia in key the academic data sentiments and view commercial Our same discussions team presented members recent have as they had June, authors. interest specialists QX. to Overall, with expressed story, the olutasidenib such as the the the at of post-Venetoclax key made began importantly, we patients the just significant activity in during olutasidenib compelling progress And and grow. continues drivers end to quarter. some in that
activities QX, In momentum we REZLIDHIA. will XX, have enable we year this building on the in second drivers Slide us those planned with addition that key of to other half continue late to expect for
is we place. a announced significant of First We leukemia in on AML treats institutional left. influence institutions community business the in that portion the centers in concentrated leukemia how key academic the these team our the now and treaters have last Recall quarter AML.
of treaters formulary REZLIDHIA leukemia the placement business who of institutional want that access, have impressive promotional leading country key in They accountable management, to of warmly with on eight heme/onc for XX I members at sales the across management. key the -- commercial They're experience REZLIDHIA hired than account have experienced marketing, functions, leukemia average, more them facilitating On these experience. will and other managers including key KOL also team development XX team. activities this and member market with We hospitals. centers. welcome top years to be calling
accomplishments move forward. to forward I'm their reporting as looking we on
and speaker our conferences, at patient we team, continue to course, non-personal our resources. we'll And other maximize the and addition institutional through HCP be channels through promotion and presence of to more programs, and access will complete and utilizing innovative half leukemia to year. continue In patients hematology key the of the hub improve for timely second we schedule during peer-to-peer
On olutasidenib more post-Venetoclax along publications side, populations the providing we're outside more planning highlighting population, or refractory cohort. additional key from the X our as as Phase pivotal relapsed mutant from well the IDHX evidence scientific with patients, trial, of
In data to generate in treat patients be IDHX relapsed story. to to current and bolster supportive difficult refractory addition, our working we'll mutant
where olutasidenib. deepen may information and KOLs team develop in of from initiatives forward to with involved HCPs of move continue medical momentum building for we education treatment understanding to need affairs And of to finally, the else we're our additional second understand our we through determine to AML our will the insights and provide to all XXXX. -- relevant looking these Overall, as half gather
And potential REZLIDHIA has a durable promising that launch, that therapies. first now treatment fail key finally on experience X targeting previous and It's refractory if during after the XX, has Slide address needs more we in months believe IDHX HCP AML. responses, of who ever shown patients the than impressive patient our the to many relapsed mutant
forward with Overall, in looking for to thanks launch launch relapsed our to for potential in future. all to forward market look with refractory are entire their and REZLIDHIA, execute we continue Thanks first My the of exciting XXXX your during and providing IDHX additional leading to I become mutant updates see to team the continuing half plan. the attention. a to efforts AML treatment you
to our on I'll provide the a now brief Raul? turn to development update call Raul back And progress. over
